Pharmaceutical (7)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BSE notifies trading members that equity shares of Goldline Pharmaceutical Limited (scrip code 544759, symbol GLPL) will be listed on the … | |||||||||||||||
BSE notifies trading members that equity shares of Goldline Pharmaceutical Limited (scrip code 544759, symbol GLPL) will be listed on the SME segment. The date of listing and security details will be communicated via a separate notice.
| |||||||||||||||
BSE revokes the suspension in trading of equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing normal trading to … | |||||||||||||||
BSE revokes the suspension in trading of equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing normal trading to resume.
| |||||||||||||||
BSE revokes the suspension of trading in equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing normal trading to … | |||||||||||||||
BSE revokes the suspension of trading in equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing normal trading to resume.
| |||||||||||||||
BSE revokes the trading suspension on equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing trading to resume. | |||||||||||||||
BSE revokes the trading suspension on equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing trading to resume.
| |||||||||||||||
BSE revokes the suspension of trading in equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing normal trading to … | |||||||||||||||
BSE revokes the suspension of trading in equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing normal trading to resume.
| |||||||||||||||
NSE notifies the listing of Sudeep Pharma Limited equity shares with effect from November 28, 2025, following IPO at issue price of Rs. 593 … | |||||||||||||||
NSE notifies the listing of Sudeep Pharma Limited equity shares with effect from November 28, 2025, following IPO at issue price of Rs. 593 per share.
| |||||||||||||||
BSE announces listing of 1000 bonus equity shares of Ipca Laboratories Ltd kept in abeyance, effective from August 26, 2025. | |||||||||||||||
BSE announces listing of 1000 bonus equity shares of Ipca Laboratories Ltd kept in abeyance, effective from August 26, 2025.
| |||||||||||||||